Chilca para Investigación anticancerígena
Baccharis latifolia — 4 estudios científicos revisados
Moderate¿Sirve Chilca para investigación anticancerígena?
La investigación científica sobre Baccharis latifolia ha explorado diversas rutas biológicas, aunque la mayoría de los estudios se encuentran en etapas tempranas de desarrollo [PMID 35391041].
Compuestos activos involucrados: Alcaloides, Distribuido, Flavonoides, Glucósido, Glucósidos, Metabol, Saponinas, Terpenos, Saponina
Evidencia Científica
Los siguientes estudios han investigado la relación entre Chilca y investigación anticancerígena:
Anti-inflammatory activity of four Bolivian Baccharis species (Compositae).
Hexanic, dichloromethanic, ethanolic and aqueous extracts from Baccharis obtusifolia HBK, Baccharis latifolia (R. et P.) Pers., Baccharis pentlandii D.C. and Baccharis subulata Wedd., plants used in the traditional medicine of South America have been studied for their in vitro anti-inflammatory activity in cellular systems. Calcium ionophore A23187-stimulated mouse peritoneal macrophages were validated as a source of cyclooxygenase-1 (COX-1) (prostaglandin E2, PGE2) and 5-lipoxygenase (5-LOX) (leukotriene C4, LTC4), and mouse peritoneal macrophages stimulated with Escherichia coli lipopolysacc
PubMed: 16202549Pharmacological activity of OST-01, a natural product from baccharis coridifolia, on breast cancer cells.
Natural products have long been a viable source of therapeutic agents, providing unique structures and mechanisms that may be beneficial for cancer treatment. Herein we first report on the anticancer activity OST-01, a natural product from Baccharis Coridifolia, on breast cancer cells, including triple-negative breast cancer (TNBC). OST-01 significantly inhibited cell proliferation and oncogenic activities of TNBC cells in vitro. OST-01 also markedly inhibited TNBC tumor growth in vivo, with > 50% reduction in tumor size compared to vehicle control treatment in different in vivo models, i.e.,
PubMed: 39920848Macrocyclic trichothecenes as antifungal and anticancer compounds.
Trichothecenes are sesquiterpenoid metabolites produced by fungi and species of the plant genus Baccharis, family Asteraceae. They comprise a tricyclic core with an epoxide at C-12 and C-13 and can be grouped into non-macrocyclic and macrocyclic compounds. While many of these compounds are of concern in agriculture, the macrocyclic metabolites have been evaluated as antiviral, anti-cancer, antimalarial and antifungal compounds. Some known cytotoxic responses on eukaryotic cells include inhibition of protein, DNA and RNA syntheses, interference with mitochondrial function, effects on cell divis
PubMed: 26572613Green Propolis: A Review of Pharmaceutical Patents with Potential Therapeutic Applications.
Green propolis is a resin produced from Baccharis dracunculifolia, which has as its main compounds flavonoids, derivatives of cinnamic acids, such as artepillin C and baccarin. This resin has antibacterial, antifungal, anti-inflammatory, antioxidant, and anticancer activities. This review aimed to analyze pharmaceutical patents containing green propolis in various formulations. The search was conducted in the National Institute of Industrial Property (INPI), the Patent Search of Spain and Latin America (Latipat-Espacenet), the World Intellectual Property Organization (WIPO), and Google Patents
PubMed: 38859772Seguridad y Precauciones
La seguridad en el uso de Chilca (Baccharis latifolia) es un área que requiere extrema precaución debido a la complejidad de sus metabolitos secundarios, como alcaloides, saponinas y terpenos, cuya toxicidad sistémica no ha sido completamente delimitada en humanos. En el caso de mujeres en periodo de embarazo y lactancia, el uso de esta planta está estrictamente contraindicado. No existe evidencia científica que garantice la ausencia de efectos teratogénicos (daños al feto) o la capacidad de los compuestos de atravesar la barrera placentaria. Asimismo, durante la lactancia, los componentes de la planta podrían excretarse en la leche materna, con riesgos potenciales para el lactante de los cuales se desconoce la magnitud. Para niños menores de 12 años, se recomienda la abstención total de su consumo, ya que sus sistemas enzimáticos hepáticos y renales están en desarrollo y podrían no metabolizar adecuadamente los glucósidos y saponinas, lo que podría derivar en toxicidad aguda. Respecto a las interacciones farmacológicas, la Chilca presenta riesgos significativos.
Otras plantas estudiadas para Investigación anticancerígena
Perfil completo: Ver todos los usos y evidencia de Chilca →